Results 71 to 80 of about 299,280 (207)

[Heterozygous familial hypercholesterolemia].

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2015
Heterozygous familial hypercholesterolemia (HeFH) is an autosomal co-dominant inherited disease associated with increased risk of early cardiovascular disease. Plasma low-density lipoprotein concentrations of the affected individuals are 2 to 3 times higher than the normal population.
Özgür Ulaş, Özcan, Sadi, Güleç
openaire   +1 more source

Patients' Attitudes Toward Detection of Heterozygous Familial Hypercholesterolemia

, 1997
BACKGROUND: Molecular biology has improved the diagnostic abilities of physicians and enabled them to identify apparently healthy persons with a high risk of genetic disease. OBJECTIVE: To examine the attitudes toward detection of disease and the present
Andersen, Lone K., Faergeman, Ole, Juul, Svend, Jensen, Henrik K.   +3 more
core   +1 more source

Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 6, November 2026.
Enlicitide (MK‐0616), an oral macrocyclic peptidyl PCSK9 inhibitor, blocks the interaction between circulating PCSK9 and hepatic LDL receptors, enhancing LDL‐C clearance from the bloodstream. This systematic review and meta‐analysis of three randomized, double‐blind, placebo‐controlled trials (n = 3593) evaluated the efficacy and safety of enlicitide ...
Muhammad Farhan, Muhammad Murtaza, Muhammad Mujtaba Rasool, Farah Khan, Hammad Amjad, Kuldeep Dalpat Rai, Sheikh Muhammad Ebtehaj Ali, Ahmed Asad Raza, Muhammad Ahmad Sohail, Abedin Samadi, Furqan Hassan   +10 more
wiley   +1 more source

Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain [PDF]

, 2019
The introduction of singular therapies, such as proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), to lower high cholesterol levels requires better classification of patients eligible for intensive lipid lowering therapy. According to the
Masana, Luis, Civeira, F., Masana, L., Mostaza, J., Ibarretxe, D., Valdivielso, P., Lopez-Miranda, Jose, Pintó, X., Plana, Nuria, Civeira, Fernando, Guijarro, C., Valdivielso, Pedro, Plana, N., Rodriguez-Borjabad, Cèlia, Pedro-Botet, J., Guijarro, Carlos, López-Miranda, J., Pinto, Xavier, Ibarretxe, Daiana, Mostaza, Jose, Pedro-Botet, Juan, Rodríguez-Borjabad, C.   +21 more
core   +1 more source

Dual Urea Cycle Dysfunction Caused by Coexisting Argininosuccinic Aciduria and Citrin Deficiency: Clinical, Biochemical, and Molecular Insights From an Exceptional Case

JIMD Reports, Volume 67, Issue 6, November 2026.
ABSTRACT Dual inherited defects affecting urea cycle function are exceptionally rare. We report the first case, to our knowledge, of the coexistence of argininosuccinic aciduria (ASA) and citrin deficiency (CD). A girl born to consanguineous Tunisian parents presented at 6 months of age with recurrent seizures, vomiting, developmental delay, and severe
Mouna Zribi, Mariem Bhouri, Safa Khatrouch, Hela Boudabous, Johannes Häberle, Mohamed Slim Abdelmoula, Amel Ben Chehida   +6 more
wiley   +1 more source

Atherosclerosis: From Pathogenesis to Therapeutic Interventions

MedComm, Volume 7, Issue 11, November 2026.
The diagram outlines the core mechanisms driving atherosclerosis, including endothelial dysfunction, inflammatory responses, phenotypic switching of smooth muscle cells, and the gut–vascular axis. It also presents the corresponding therapeutic approaches now under development, such as gene therapies, immunotherapies, and nanotechnology platforms ...
Enge Zhou, Chenxi Zhan, Yuting Li, Yi Zeng, Renfei Luo, Xin Ouyang, Shixing Liu, Renqiang Yang, Nianlong Yan, Long Jiang   +9 more
wiley   +1 more source

Hypocholesterolemia in liver and cardiovascular disease: Friend or foe?

Journal of Internal Medicine, Volume 300, Issue 5, Page 572-589, November 2026.
Abstract Hypocholesterolemia is perceived as benign given its association with lower cardiovascular risk. However, genetic and epidemiological evidence indicates that persistently low levels of low‐density lipoprotein cholesterol (LDL‐C) and apolipoprotein B (ApoB) arise from distinct biological mechanisms with different hepatic implications ...
Valentina Flagiello, Emelie Barreby, Umberto Vespasiani‐Gentilucci, Stefano Romeo   +3 more
wiley   +1 more source

NSG Mice Lacking Apoe: An Immunodeficient Mouse Model of Atherosclerosis

The FASEB Journal, Volume 40, Issue 20, 31 October 2026.
Immunodeficient NSG mice lacking the Apoe gene develop atherosclerosis when placed on high fat diet (HFD). These mice support engraftment with human CD34+ hematopoietic stem cells. The NSG‐ApoEKO mice can be used in humanized mouse models to examine human‐specific immune disease mechanisms. Created in BioRender.
Hannah R. Megathlin, Lisa Burzenski, David A. Coleman, Blaze Albert, Michelle L. Farley, Michael A. Brehm, Dale L. Greiner, Leonard D. Shultz   +7 more
wiley   +1 more source

The treatment of heterozygous familial hypercholesterolemia — a local perspective

Endokrynologia Polska, 2021
none.
openaire   +3 more sources

Phenotypic Variation in Heterozygous Familial Hypercholesterolemia

, 1998
—Familial hypercholesterolemia (FH) is caused by mutations in the LDL receptor (LDLR) gene and is usually associated with hypercholesterolemia, lipid deposition in tissues, and premature coronary artery disease (CAD).
Xi-Ming Sun, Jiri J. Frohlich, Simon N. Pimstone, Michael R. Hayden, Christele du Souich, Anne K. Soutar   +5 more
core   +1 more source